INmune Bio Statistics
Total Valuation
INmune Bio has a market cap or net worth of $30.04 million. The enterprise value is $6.59 million.
Important Dates
The last earnings date was Monday, March 30, 2026, after market close.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
INmune Bio has 26.59 million shares outstanding. The number of shares has increased by 24.13% in one year.
| Current Share Class | 26.59M |
| Shares Outstanding | 26.59M |
| Shares Change (YoY) | +24.13% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 17.01% |
| Owned by Institutions (%) | 19.41% |
| Float | 20.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 606.14 |
| Forward PS | n/a |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 131.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.55, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.55 |
| Quick Ratio | 3.48 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -165.16% and return on invested capital (ROIC) is -67.65%.
| Return on Equity (ROE) | -165.16% |
| Return on Assets (ROA) | -53.66% |
| Return on Invested Capital (ROIC) | -67.65% |
| Return on Capital Employed (ROCE) | -128.97% |
| Weighted Average Cost of Capital (WACC) | 8.66% |
| Revenue Per Employee | $2,273 |
| Profits Per Employee | -$2.09M |
| Employee Count | 22 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.97% in the last 52 weeks. The beta is 0.85, so INmune Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -84.97% |
| 50-Day Moving Average | 1.40 |
| 200-Day Moving Average | 2.09 |
| Relative Strength Index (RSI) | 38.39 |
| Average Volume (20 Days) | 532,778 |
Short Selling Information
The latest short interest is 3.26 million, so 12.25% of the outstanding shares have been sold short.
| Short Interest | 3.26M |
| Short Previous Month | 3.81M |
| Short % of Shares Out | 12.25% |
| Short % of Float | 15.80% |
| Short Ratio (days to cover) | 6.00 |
Income Statement
In the last 12 months, INmune Bio had revenue of $50,000 and -$45.93 million in losses. Loss per share was -$1.86.
| Revenue | 50,000 |
| Gross Profit | 50,000 |
| Operating Income | -30.87M |
| Pretax Income | -45.93M |
| Net Income | -45.93M |
| EBITDA | -30.79M |
| EBIT | -30.87M |
| Loss Per Share | -$1.86 |
Full Income StatementBalance Sheet
The company has $24.75 million in cash and $1.03 million in debt, with a net cash position of $23.72 million or $0.89 per share.
| Cash & Cash Equivalents | 24.75M |
| Total Debt | 1.03M |
| Net Cash | 23.72M |
| Net Cash Per Share | $0.89 |
| Equity (Book Value) | 23.52M |
| Book Value Per Share | 0.88 |
| Working Capital | 21.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.58 million and capital expenditures -$1.04 million, giving a free cash flow of -$23.62 million.
| Operating Cash Flow | -22.58M |
| Capital Expenditures | -1.04M |
| Depreciation & Amortization | 84,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -23.62M |
| FCF Per Share | -$0.89 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -61,738.00% |
| Pretax Margin | -91,866.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
INmune Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.13% |
| Shareholder Yield | -24.13% |
| Earnings Yield | -151.56% |
| FCF Yield | -77.95% |
Analyst Forecast
The average price target for INmune Bio is $5.40, which is 377.88% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.40 |
| Price Target Difference | 377.88% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 382.51% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
